Levetiracetam
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Absence Seizures
Conditions
Absence Seizures
Trial Timeline
May 1, 2000 → May 1, 2003
NCT ID
NCT00545012About Levetiracetam
Levetiracetam is a phase 2 stage product being developed by UCB for Absence Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00545012. Target conditions include Absence Seizures.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340064 | Phase 3 | Completed |
| NCT01618877 | Phase 1 | Completed |
| NCT01407523 | Phase 2 | Completed |
| NCT01398956 | Phase 3 | Completed |
| NCT01292837 | Phase 3 | Completed |
| NCT01063764 | Phase 3 | Completed |
| NCT00505934 | Phase 2 | Completed |
| NCT00627133 | Phase 2 | Withdrawn |
| NCT00535392 | Phase 2 | Completed |
| NCT00376766 | Phase 3 | Terminated |
| NCT00361010 | Pre-clinical | Completed |
| NCT01318408 | Approved | Completed |
| NCT00367432 | Phase 3 | Completed |
| NCT00291655 | Phase 3 | Completed |
| NCT00324454 | Phase 2 | Completed |
| NCT00319605 | Pre-clinical | Completed |
| NCT00307450 | Approved | Completed |
| NCT00279617 | Phase 3 | Completed |
| NCT00325182 | Approved | Completed |
| NCT00252954 | Approved | Completed |
Competing Products
9 competing products in Absence Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| topiramate | Johnson & Johnson | Phase 2 | 52 |
| Idelalisib | Gilead Sciences | Pre-clinical | 22 |
| rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid | Pfizer | Pre-clinical | 22 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Brivaracetam | UCB | Phase 3 | 74 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |
| BMB-101 | Bright Minds Biosciences | Phase 2 | 47 |